Association of Four ERCC1 and ERCC2 SNPs with Survival of Bone Tumour Patients

Hao, Tong; Wang, Feng; Zhang, Jie; Sun, Yongjian; Wang, Gang

doi:10.7314/apjcp.2012.13.8.3821

Cited by 33 publications

(26 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study indicated ERCC2 A/A genotype also presented a higher rate of response to chemotherapy, and ERCC2 A/A was significantly associated with higher risk of death from osteosarcoma. Previous studies showed ERCC2 was associated with response to chemotherapy among osteosarcoma (Caronia et al, 2009), and survival of this cancer (Hao et al, 2012). Our results here are in line with these previous studies.…”

Section: Discussionsupporting

confidence: 93%

“…In this process, the genes involved are the ones that control drug absorption, distribution, metabolism, and excretion. Our previous study indicated ERCC1 and ERCC2 might have a role in the prognosis of bone tumor (Hao et al, 2012). Glutathione S-transferases (GSTs) are a family of cytosolic enzymes involved in the detoxification of various exogenous as well as endogenous reactive species (Ketterer, 1998;Hengstler et al, 1998).…”

Section: Introductionmentioning

confidence: 99%

“…We previously performed a study of the nucleotide excision DNA repair pathway in relation to response to cisplatin and observed an association between osteosarcoma outcome and a polymorphism in ERCC1 and ERCC2 (Hao et al, 2012). In this study we studies a comprehensive set of three SNPs and identified the prognostic genetic factors for the chemotherapeutic agents, and their association with drug response.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Glutathione S-transferase P1 and DNA Polymorphisms with the Response to Chemotherapy and the Prognosis of Bone Tumor

Yang

Li²,

Bao³

2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Osteosarcoma is the most common primary bone malignancy in children and adolescents, and its clinical outcome is poor. We evaluated the response of GSTP1, ERCC1 and ERCC2 to chemotherapy among osteosarcoma patients, and the role of these genes on the prognosis of osteosarcoma. 187 patients with osteosarcoma were administered with methotrexate, cisplatin/adriamycin, actinomycin D, cyclophosphamide, or vincristine treatment. GSTP1, ERCC1 and ERCC2 polymorphism was genotyped by PCR-RFLP assay. The results showed the average survival time of 187 patients were 38.4 months. 97 patients showed response to neoadjuvant chemotherapy. The GSTP1 Val and ERCC2 A/A genotypes had significantly higher rates of response to chemotherapy, with adjusted OR (95% CI) of 2.19 (1.15-6.21) and 2.88 (1.14-13.25). Individuals with ERCC2 A/A genotype were likely to have a lower risk of death from oseosarcoma, and the adjusted HR was 0.32 (0.13-0.95). Our study indicated test of GSTP1 and ERCC2 Lys751Gln polymorphisms might be a candidate pharmacogenomic factors to be explored in the future to identify the osteosarcoma patients who might benefit from chemotherapy.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Glutathione S-transferase P1 and DNA Polymorphisms with the Response to Chemotherapy and the Prognosis of Bone Tumor

Yang

Li²,

Bao³

2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…However, for osteosarcoma, the results have been inconsistent (Caronia et al, 2009;Hao et al, 2012;Yang et al, 2012;Li et al, 2014a). Therefore, we aimed to evaluate the influence of four SNPs in ERCC1 and ERCC2 on the response to cisplatin-based treatment and the clinical outcome in patients with osteosarcoma.…”

Section: Introductionmentioning

confidence: 99%

Association between ERCC1 and ERCC2 gene polymorphisms and chemotherapy response and overall survival in osteosarcoma

Jiang

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. We aimed to evaluate the influence of four SNPs in ERCC1 and ERCC2 on the response to cisplatin-based treatment and on clinical outcome in patients with osteosarcoma. We identified 186 patients with osteosarcoma diagnosed between April 2009 and April 2011 who were eligible for inclusion in our study. Genotyping of ERCC1 rs11615, rs3212986, and rs2298881; and ERCC2 rs1799793 and rs13181 was conducted by a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. By conditional logistic regression analysis, patients carrying the CC genotypes of ERCC1 rs11615 and rs2298881 were shown to be more likely to have good response to chemotherapy when compared with patients carrying wildtype genotypes; the ORs (95%CIs) were 2.56 (1.02-7.35) and 3.01 (1.07-9.71), respectively. By Cox regression analysis, individuals carrying the CC genotype of ERCC1 rs11615 were associated with longer overall survival time and decreased risk of death from osteosarcoma; the hazards 10146 Z.H. Cao et al. ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 14 (3): 10145-10151 (2015) ratio (95%CI) was 0.32 (0.07-0.98). In summary, our results suggested that the ERCC1 rs11615 and rs2298881 polymorphisms play important roles in the response to chemotherapy mediated by the DNA repair pathway and in the clinical outcome of osteosarcoma.

show abstract

“…Our previous pharmacogenetic studies have shown that the polymorphism of nucleotide excision DNA repair pathway correlates with response to chemotherapy and clinical outcome of osteosarcoma (Hao et al, 2012). The genetic variation may affect the global response to treatment or cause adverse drug events.…”

Section: Introductionmentioning

confidence: 99%

Effect of variation of ABCB1 and GSTP1 on osteosarcoma survival after chemotherapy

Li¹,

Tian²,

Jiang³

et al. 2014

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. We conducted a comprehensive study to investigate the role of genes involved in metabolic and transport pathways in response to chemotherapy and clinical outcome of osteosarcoma patients. Genotyping of seven gene polymorphisms was performed on a 384-well plate format on the Sequenom MassARRAY platform in 162 patients with osteosarcoma. We studied the correlation of the seven gene polymorphisms with response to chemotherapy and clinical outcome of patients. Individuals with the ABCB1 TT genotype had a higher probability of responding poorly to chemotherapy, indicated by an odds ratio (OR) of 2.64 (95%CI = 1.04-6.83). Similarly, the genotype of GSTP1 GG was significantly associated with improved responses to chemotherapy, indicated by an OR of 3.33 (95%CI = 1.26-8.99). The ABCB1 TT and GSTP1 GG genotypes were significantly associated with a shorter overall survival (OS). Our study found that two gene polymorphisms in two transporter genes and one Phase II metabolism enzymes are associated with response to chemotherapy and ABCB1 and GSTP1 and osteosarcoma survival OS in osteosarcoma patients, suggesting the potential of the two gene polymorphisms as prognostic biomarkers for osteosarcoma.

show abstract

Association of Four ERCC1 and ERCC2 SNPs with Survival of Bone Tumour Patients

Cited by 33 publications

References 8 publications

Glutathione S-transferase P1 and DNA Polymorphisms with the Response to Chemotherapy and the Prognosis of Bone Tumor

Glutathione S-transferase P1 and DNA Polymorphisms with the Response to Chemotherapy and the Prognosis of Bone Tumor

Association between ERCC1 and ERCC2 gene polymorphisms and chemotherapy response and overall survival in osteosarcoma

Effect of variation of ABCB1 and GSTP1 on osteosarcoma survival after chemotherapy

Contact Info

Product

Resources

About